Yüklüyor......
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
BACKGROUND: Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. METHODS: The...
Kaydedildi:
| Yayımlandı: | J Transl Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6998840/ https://ncbi.nlm.nih.gov/pubmed/32014010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02231-0 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|